A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine / 결핵및호흡기질환
Youn-Jung PARK; Keun-Suk YANG; Hong-Soon JUNG; Hee-Chul NAM; Seung-Hye JUNG; Boo-Gyoung KIM; Ka-Young KIM; Jung-Ho KIM; Young-Ok KIM; Yu-Seon YUN.
Tuberculosis and Respiratory Diseases
; : 207-211, 2012.
Artículo
en Ko
| WPRIM | ID: wpr-154555
Hemolytic uremic syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS arises from a wide spectrum of conditions, and chemotherapeutic agents have been reported to be associated with HUS, including Mitomycin, Cisplatin, Bleomycin, and Gemcitabine. A 76-year-old man treated with Gemcitabine due to non-small cell lung cancer developed clinical and laboratory findings compatible with HUS. Gemcitabine was ceased and hemodialysis and plasma exchange were utilized and he recovered. A high level of suspicion for HUS is necessary when cancer patients are treated with Gemcitabine, and prompt recognition and treatment are also essential.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados